NCT00480987View on ClinicalTrials.gov

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Myelodysplastic SyndromesAcute Myeloid LeukemiaLeukemia
Interventions
DRUG

Oxaliplatin

30 mg/m\^2 IV days 1-4

DRUG

Fludarabine

30 mg/m\^2 IV days 2-6

DRUG

Cytarabine

500 mg/m\^2 by IV continuous infusion days 2-6

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER